Malignant gastrointestinal neuroectodermal tumour (GNET) is an extremely rare neoplasm first described by Zambrano in 2003 as clear cell sarcoma like tumor of the gastrointestinal tract. In contrast to clear cell sarcoma, it has giant osteoclast cells and shows diffuse and intense positivity for S-100 with no immunohistochemical or ultrastructural melanocyte differentiation. We present the first cases of GNET reported in South America, occurring in Peru. Two cases of GNET, one in a female and one in a male, both between 60 and 70 years of age, were referred to our hospital for reevaluation. One underwent further treatment in our centre, but with an unfavourable evolution. Pathologists should be aware of the diagnostic criteria for GNET in order to avoid misdiagnosis due to confusion with other non-epithelial gastrointestinal neoplasms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.patol.2020.07.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute Jejunal Diverticulitis Induced by a Malignant Gastrointestinal Neuroectodermal Tumor: A Case Report.
Cureus
December 2024
Surgical Oncology, Prince Sultan Military Medical City, Riyadh, SAU.
Small intestinal diverticula induced by malignant mesenchymal tumors are extremely rare clinical entities. We present the case of a 46-year-old female who reported a one-week history of worsening generalized abdominal pain accompanied by constipation. A computed tomography (CT) scan of her abdomen revealed an ulcerative mass at the proximal/midjejunal junction, suggestive of jejunal diverticulitis.
View Article and Find Full Text PDFEstimating prognosis of gastric neuroendocrine neoplasms using machine learning: A step towards precision medicine.
World J Gastrointest Oncol
December 2024
Department of Gastrointestinal Surgery, Changzhi People's Hospital, Changzhi 046000, Shanxi Province, China.
Article Synopsis
- Survival rates after surgery for gastric neuroendocrine neoplasms (g-NENs) are low, and traditional prognostic models like the CoxPH show limited ability to predict patient outcomes post-surgery.
- Machine learning techniques, particularly the random survival forest (RSF) model, can analyze complex data to improve predictions of survival outcomes.
- The study highlights that the RSF model, which uses the lymph node ratio (LNR), is more effective than CoxPH in predicting disease-specific survival in g-NEN patients and could lead to better personalized treatment strategies.
Prognostic factors in clear cell sarcoma: an analysis of soft tissue sarcoma in 43 cases.
J Cancer Res Clin Oncol
November 2024
Department of Medical Oncology and Sarcoma Center, West German Cancer Center, Medical School, University Duisburg-Essen, Essen, Germany.
Article Synopsis
- Clear cell sarcoma (CCS) and its similar tumor, malignant gastrointestinal neuroectodermal tumor/sarcoma (GINET), often lead to local and distant relapses, with limited success from systemic treatments.
- A study analyzed data from 43 patients, revealing a 5-year overall survival rate of 42%, with most tumors being EWSR1::ATF1-translocation-positive and showing a high rate of metastasis.
- The findings highlighted that complete tumor resection significantly improves survival rates compared to incomplete resection, while systemic treatments and radiation were largely ineffective.
Malignant Gastrointestinal Neuroectodermal Tumor, a Rare Neoplasm, Presenting With Hemoperitoneum and Malena: A Case Report.
Cureus
October 2024
General Surgery, Topiwala National Medical College and Bai Yamunabai Laxman Nair Charitable Hospital, Mumbai, IND.
Malignant gastrointestinal neuroectodermal tumor (GNET) are rare malignant mesenchymal tumors. The tumor can present with various symptoms like abdominal pain, anorexia, or small bowel obstruction. Here, we present a case of small intestinal GNET who presented with gastrointestinal bleed and hemoperitoneum, a rare presentation of this disease.
View Article and Find Full Text PDFExtra-abdominal and intra-abdominal FET::CREM fusion mesenchymal neoplasms: comparative clinicopathological study of 9 new cases further supporting a distinct potentially aggressive sarcoma and report of novel sites.
Virchows Arch
December 2024
Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan.
Article Synopsis
- - The study highlights the rapid growth in understanding FET::CREB fusion mesenchymal tumors, which now includes aggressive neoplasms not classified by WHO, specifically focusing on newly reported intra-abdominal and extra-abdominal cases with specific fusions like EWSR1::CREM and FUS::CREM.
- - Nine additional tumors were analyzed, involving various locations and a wide age range for patients, with treatment primarily consisting of radical surgery and some receiving additional chemotherapy or radiation.
- - The aggressive nature of these tumors is emphasized, with follow-up showing significant disease progression in some patients, while also noting similarities in immunophenotype across tumor subtypes, indicating a broader classification of potentially dangerous neoplasms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!